578 related articles for article (PubMed ID: 8612391)
21. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase.
Engelbrecht I; Petzer JP; Petzer A
Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034
[TBL] [Abstract][Full Text] [Related]
22. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors.
Talati R; Reinhart K; Baker W; White CM; Coleman CI
Parkinsonism Relat Disord; 2009 Aug; 15(7):500-5. PubMed ID: 19167259
[TBL] [Abstract][Full Text] [Related]
23. The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Sovijärvi A; Kaakkola S; Gordin A; Teräväinen H
Clin Neuropharmacol; 2001; 24(1):50-7. PubMed ID: 11290882
[TBL] [Abstract][Full Text] [Related]
24. Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease.
Müller T; Kolf K; Ander L; Woitalla D; Muhlack S
Clin Neuropharmacol; 2008; 31(3):134-40. PubMed ID: 18520980
[TBL] [Abstract][Full Text] [Related]
25. Different metabolism of norepinephrine and epinephrine by catechol-O-methyltransferase and monoamine oxidase in rats.
Eisenhofer G; Finberg JP
J Pharmacol Exp Ther; 1994 Mar; 268(3):1242-51. PubMed ID: 8138937
[TBL] [Abstract][Full Text] [Related]
26. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.
Kaakkola S
Int Rev Neurobiol; 2010; 95():207-25. PubMed ID: 21095464
[TBL] [Abstract][Full Text] [Related]
27. In vivo assessment of catechol O-methyltransferase activity in rabbit skeletal muscle.
Fujii T; Yamazaki T; Akiyama T; Sano S; Mori H
Auton Neurosci; 2004 Apr; 111(2):140-3. PubMed ID: 15182744
[TBL] [Abstract][Full Text] [Related]
28. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR.
Paija O; Laine K; Kultalahti ER; Leinonen M; Huupponen R; Gordin A; Reinikainen K
Clin Neuropharmacol; 2005; 28(3):115-9. PubMed ID: 15965309
[TBL] [Abstract][Full Text] [Related]
29. Erythrocytes catechol-o-methyl transferase activity is up-regulated after a 3-month treatment by entacapone in parkinsonian patients.
Maltête D; Cottard AM; Mihout B; Costentin J
Clin Neuropharmacol; 2011; 34(1):21-3. PubMed ID: 21164341
[TBL] [Abstract][Full Text] [Related]
30. COMT inhibition by entacapone does not affect growth hormone or prolactin secretion in healthy volunteers.
Keränen T; Gordin A; Koulu M; Scheinin M; Antila S; Sundberg S; Wikberg T
J Neural Transm (Vienna); 1996; 103(6):729-36. PubMed ID: 8836934
[TBL] [Abstract][Full Text] [Related]
31. The effects of the COMT inhibitor nitecapone for one week on exercise haemodynamics and catecholamine disposition.
Sundberg S; Scheinin M; Ojala-Karlsson P; Akkila J; Gordin A
Eur J Clin Pharmacol; 1993; 44(3):287-90. PubMed ID: 8491246
[TBL] [Abstract][Full Text] [Related]
32. Norepinephrine metabolites in plasma as indicators of pharmacological inhibition of monoamine oxidase and catechol O-methyltransferase.
Scheinin M; Illi A; Koulu M; Ojala-Karlsson P
Adv Pharmacol; 1998; 42():367-70. PubMed ID: 9327918
[No Abstract] [Full Text] [Related]
33. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers.
Keränen T; Gordin A; Harjola VP; Karlsson M; Korpela K; Pentikäinen PJ; Rita H; Seppälä L; Wikberg T
Clin Neuropharmacol; 1993 Apr; 16(2):145-56. PubMed ID: 8477410
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition.
Rouru J; Gordin A; Huupponen R; Huhtala S; Savontaus E; Korpela K; Reinikainen K; Scheinin M
Eur J Clin Pharmacol; 1999 Aug; 55(6):461-7. PubMed ID: 10492060
[TBL] [Abstract][Full Text] [Related]
35. The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers.
Van Haarst AD; Van Gerven JM; Cohen AF; De Smet M; Sterrett A; Birk KL; Fisher AL; De Puy ME; Goldberg MR; Musson DG
Br J Clin Pharmacol; 1999 Aug; 48(2):190-6. PubMed ID: 10417495
[TBL] [Abstract][Full Text] [Related]
36. [Inhibition of the COMPT with entacapone in the treatment of motor fluctuations in Parkinson disease].
Kulisevsky J
Neurologia; 1999; 14(7):349-58. PubMed ID: 10570622
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man.
Bitsios P; Langley RW; Tavernor S; Pyykkö K; Scheinin M; Szabadi E; Bradshaw CM
Br J Clin Pharmacol; 1998 Jun; 45(6):551-8. PubMed ID: 9663810
[TBL] [Abstract][Full Text] [Related]
38. Entacapone in the management of Parkinson's disease.
Henchcliffe C; Waters C
Expert Opin Pharmacother; 2002 Jul; 3(7):957-63. PubMed ID: 12083995
[TBL] [Abstract][Full Text] [Related]
39. Exercise hemodynamics and catecholamine metabolism after catechol-O-methyltransferase inhibition with nitecapone.
Sundberg S; Scheinin M; Ojala-Karlsson P; Kaakkola S; Akkila J; Gordin A
Clin Pharmacol Ther; 1990 Oct; 48(4):356-64. PubMed ID: 2225697
[TBL] [Abstract][Full Text] [Related]
40. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.
Valkovic P; Benetin J; Blazícek P; Valkovicová L; Gmitterová K; Kukumberg P
Parkinsonism Relat Disord; 2005 Jun; 11(4):253-6. PubMed ID: 15878587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
